Figure 5.

Pain-relieving effect of (a) 4 and (b) 13 on oxaliplatin-induced thermal allodynia in mice. Cold plate test. Oxaliplatin (2.4 mg kg⁻¹) was dissolved in 5% glucose solution and intraperitoneal (i.p.) administered for 5 consecutive days every week for 14 days. Starting from day 14, compounds were dissolved in saline solution and intrathecally administered at the doses of 1 nmol/mouse and 3 nmol/mouse in a final volume of 5 μL. Pain-related behavior (i.e., lifting and licking of the hind paw) was observed and the time (s) of the first sign was recorded. ** p < 0.01 vs. vehicle + vehicle treated animals; ^ p < 0.05 and ^^ p < 0.01 vs. oxaliplatin + vehicle treated animals. Each value represents the mean ± S.E.M. of 10 mice performed in two different experimental sets (10 mice treated with oxaliplatin and 10 control mice). The analysis of variance was performed by one-way ANOVA. A Bonferroni’s significant difference procedure was used as post hoc comparison.